Cancer Treatment in China 2026: CAR-T Therapy $50,000-$100,000 vs $300,000-$500,000 in the US

If you’ve been diagnosed with cancer, gotten the US price quote (CAR-T at $300,000-500,000+, immunotherapy at $100,000-200,000/year, transplant at $300,000-800,000), and wondered whether there’s a serious option at a fraction of the cost — this guide is for you. China in 2026 is the global cost leader for cancer treatment at JCI-quality public hospitals: CAR-T at $50,000-100,000 (1/5 the US price), 5+ approved domestic CAR-T products including Fosun Kite’s axicabtagene ciloleucel (same molecule as US Yescarta), the world’s 2nd largest oncology clinical trial portfolio (4,800+ active trials), and Hainan Boao — the only place in mainland China where a foreigner can access US FDA-approved cancer drugs not yet approved by the Chinese NMPA. Top centers (Fudan Shanghai Cancer Center, PUMCH Oncology, Beijing Cancer Hospital, Sun Yat-sen Cancer Center, West China Hospital, Yanda Ludaopei) treat the most gastric, liver, esophageal, and nasopharyngeal cancer cases in the world. The honest trade-off: for most adult solid tumors and hematologic malignancies, China in 2026 is a genuinely equivalent treatment option at 1/5 the cost. For rare pediatric sarcomas, some rare leukemias, and very late-stage refractory disease, US MD Anderson or Memorial Sloan Kettering may still be the right first call.

This article is part of our medical tourism cluster. For the framework, see the P0 medical tourism guide. For city deep dives, see Beijing guide, Shanghai guide, Hainan Boao guide, and Chengdu guide. For process, see our medical visa guide, insurance & payment guide, and TCM & wellness guide.

Why China for cancer treatment in 2026: 5 reasons

1. CAR-T at 1/5 the US price. China approved its first CAR-T (Fosun Kite Yescarta, axicabtagene ciloleucel) in 2021 and has since approved 5+ domestic products. Pricing is $50,000-100,000 per course vs $300,000-500,000+ in the US. Products are produced at NMPA-audited facilities with full apheresis, manufacturing, and inpatient CAR-T management. For a relapsed/refractory DLBCL patient facing a $373,000 US Yescarta list price, China is now the rational economic choice at the same clinical efficacy. See CAR-T deep dive below.

2. World-class oncology centers with English-speaking international services. The top 6 cancer hospitals (Fudan Shanghai Cancer Center, PUMCH, Beijing Cancer Hospital, Sun Yat-sen Cancer Center, West China Hospital, Yanda Ludaopei) are JCI-accredited or top-3 Chinese public tertiary-A hospitals, with dedicated international patient centers, English-speaking oncologists (many with US/UK training), US-board-certified pathologists, and the same Da Vinci surgical robots, CyberKnife, proton therapy, and PET-CT as US centers. Fudan treats 1.5M+ outpatient visits per year — comparable to MD Anderson’s volume.

3. The world’s 2nd largest oncology clinical trial portfolio. As of early 2026, China has 4,800+ active oncology trials (vs 7,000+ in the US, 1,500+ in the EU). Chinese-developed oncology drugs (PD-1/PD-L1 inhibitors like toripalimab, sintilimab, tislelizumab, camrelizumab; CDK4/6, BTK, next-generation CAR-T) are increasingly leading global development. For some indications (3rd-generation EGFR inhibitors, novel bispecifics, allogeneic CAR-T), Chinese trials are the only place outside the US. See clinical trials section below.

4. Integrated Chinese-Western oncology with TCM as supportive care. Every top oncology hospital has a TCM department alongside medical, surgical, and radiation oncology. TCM is well-documented for chemotherapy-induced nausea, fatigue, bone marrow suppression, cancer pain, and post-surgical recovery (per Cochrane reviews and CSCO guidelines), and dramatically cheaper than equivalent Western supportive care. See TCM section below.

5. Hainan Boao for cutting-edge US/EU drugs not yet approved in mainland China. Boao Lecheng International Medical Tourism Pilot Zone is the only place in mainland China where a foreigner can access US FDA-approved drugs (post-FDA, pre-mainland-NMPA) for legal clinical use. For cancer patients who specifically need a US-approved drug that hasn’t received Chinese NMPA approval yet, Boao is the only option. See Boao section below.

The honest trade-offs: (1) For rare pediatric cancers, some rare leukemias, and very late-stage refractory disease, US MD Anderson or Memorial Sloan Kettering may still be the right first call — they have 2-3x more Phase 1 oncology trials and longer experience with ultra-rare molecular subtypes. (2) Language barrier outside the international wing — always request the international/foreigners’ section. (3) No unified medical records system — request an English discharge summary and DICOM imaging after every visit. (4) Cross-border insurance rarely covers pre-existing cancer — most foreign patients self-pay. (5) Treatment trip is 30-90 days for most protocols, not 2 weeks. For 80% of adult solid tumors and hematologic malignancies, the trade-offs are minor.

2026 cancer treatment cost comparison: China vs US vs UK

All prices in USD, single course of treatment at a top-3 Chinese oncology hospital international wing, no insurance. Airfare, accommodation, and companion costs are separate — see the itinerary section.

Why China is cheaper: Three structural reasons. (1) Chinese-developed biosimilars and generics — the leading PD-1 inhibitors (toripalimab/君实, sintilimab/信达, tislelizumab/百济神州, camrelizumab/恒瑞) are priced at 10-20% of US pembrolizumab/nivolumab list prices. (2) Centralized NHSA bulk procurement of chemotherapy drugs — multiple rounds since 2018 have cut chemo prices 50-80% (the 2024 NHSA round included major chemo agents and supportive care drugs at 30-50% of prior prices). (3) Public hospital cross-subsidization of international patients — the international wing pricing covers higher nurse-to-patient ratios, English-speaking coordinators, and private rooms, but underlying drug and procedure costs remain at public-hospital rates.

What to factor in for total trip cost:

• Treatment cost (above table)
• Round-trip airfare from US/UK/EU: $800-1,800 per person
• 30-60 days mid-tier hotel/serviced apartment near hospital: $3,000-9,000
• Companion (highly recommended, often required for major surgery/CAR-T): $4,000-12,000
• Meals + local transport: $1,000-2,500
• Medical visa (if M-visa): $30-150 per person
• Tumor molecular profiling, repeat scans, biopsy review: $1,000-3,000
• Post-treatment medications to take home: $1,000-5,000
• Total for 45-day cancer treatment trip + 1 companion: $40,000-90,000 (vs $300,000-500,000+ in the US for the same CAR-T alone)

For more cost framework, see our insurance & payment guide and medical tourism P0 guide.

Top 6 cancer hospitals in China for foreigners

Six hospitals account for the majority of foreign cancer patient care in China. Each has a dedicated international patient center, English-speaking coordinators, and a clear specialty focus.

1. Fudan University Shanghai Cancer Center (复旦大学附属肿瘤医院) — the #1 overall choice. China’s #1 oncology hospital by research output and one of the top 2 by volume (1.5M+ outpatient visits/year). 7,000+ beds, JCI-accredited, English-speaking international patient center, US-board-certified pathologists, and the deepest experience in breast, gastric, colorectal, pancreatic, lymphoma, and CAR-T. For most foreign patients, Fudan is the right first call. See Shanghai guide.

2. Peking Union Medical College Hospital Oncology (PUMCH, 中国医学科学院北京协和医院肿瘤科) — the prestige choice. Consistently ranked #1 or #2 in China overall (the “Mayo Clinic of China”). Best for complex solid tumors, rare cancers, sarcoma, and second opinions. The VIP international clinic (东单院区国际医疗部) is in central Beijing, with US/UK-trained oncologists and the hospital’s renowned multidisciplinary tumor board reviewing every complex case. PUMCH is also the strongest choice for second opinions — the pathology department re-reviews biopsies sent from abroad. See Beijing guide.

3. National Cancer Center / Beijing Cancer Hospital (中国医学科学院肿瘤医院, NCC/CICAMS) — the lung and esophageal leader. China’s national cancer center in Beijing, treats the most lung cancer cases in China and is the top center for lung, esophageal, lymphoma, and head & neck cancers. Runs China’s largest lung cancer screening program with the deepest experience in image-guided interventions (ablation, bronchoscopy, EBUS). For lung cancer specifically, NCC is the right first call.

4. Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心, SYSUCC) — the world’s #1 for NPC and the South China hub. China’s #1 oncology hospital by volume (1.7M+ outpatient visits per year), located in Guangzhou. SYSUCC is the world’s leading center for nasopharyngeal carcinoma (NPC) — a cancer 5-10x more common in southern China and SE Asia than in Western countries. Also top for liver cancer, breast, and colorectal. Convenient for SE Asian patients (2-hour flight from Singapore, Bangkok, Kuala Lumpur).

5. West China Hospital of Sichuan University Oncology (四川大学华西医院肿瘤科) — the western China anchor. Consistently ranked in China’s top 5 hospitals overall, with strong oncology department, JCI-accredited, and the leading Phase 1 oncology trial center in western China. Top for colorectal, gastric, lung, and biliary/pancreatic cancers. A strong alternative for combining treatment with TCM (Chengdu is the TCM heartland). See Chengdu guide.

6. Hebei Yanda Ludaopei Hospital (河北燕达陆道培医院) — the CAR-T and bone marrow transplant center. China’s #1 hematology / CAR-T / BMT center, founded by Dr. Lu Daopei (the “father of Chinese bone marrow transplantation”). Treats the most CAR-T and allogeneic HSCT cases in China, runs 30+ active CAR-T clinical trials, and is the most experienced Chinese center for managing CAR-T complications (CRS, ICANS, HLH, prolonged cytopenia). Located in Hebei province (1 hour from Beijing). For CAR-T specifically, Yanda Ludaopei is the right first call.

For the broader city framework, see the Beijing guide, Shanghai guide, and Boao guide.

CAR-T therapy in China

CAR-T is the most expensive single treatment in modern oncology, and the single biggest reason foreign patients travel to China for cancer care.

What CAR-T is and when it’s used. CAR-T is a personalized cell therapy where a patient’s own T-cells are genetically engineered to express a chimeric antigen receptor targeting a specific tumor antigen, then reinfused. Currently standard-of-care for relapsed/refractory B-cell lymphomas (DLBCL, PMBCL, FL, MCL), R/R multiple myeloma (after BCMA-targeted therapies), and R/R B-cell ALL. The process takes 4-6 weeks: leukapheresis → manufacturing (2-3 weeks) → lymphodepleting chemotherapy → CAR-T infusion → 2-4 week inpatient monitoring for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and prolonged cytopenia.

Approved CAR-T products in China (as of 2026):

• Axicabtagene ciloleucel (奕凯达, Fosun Kite Yescarta) — for R/R DLBCL and FL. Same molecule as US Yescarta. China price: ~$80,000-100,000 per course.
• Relmacabtagene autoleucel (Carteyva, JW Therapeutics) — for R/R large B-cell lymphoma. China price: ~$60,000-90,000.
• Equecabtagene autoleucel (伊基奥仑赛, IASO Bio) — for R/R multiple myeloma (BCMA-targeted). China price: ~$70,000-100,000.
• Additional products for multiple myeloma, ALL, and other indications are approved or in late-stage trials.

Clinical trial CAR-T (often the most cutting-edge, sometimes the only option):

• Allogeneic CAR-T (off-the-shelf, no apheresis) — multiple Phase 1/2 trials at Yanda Ludaopei, Tongji, and several Boao facilities. Ideal for patients who can’t wait 3-4 weeks for autologous manufacturing.
• Dual-target CAR-T (e.g., CD19/CD22, BCMA/GPRC5D) — for relapse after single-target CAR-T.
• CAR-T for solid tumors — early-phase trials in HCC, gastric, glioblastoma, pancreatic, sarcoma. Mostly at Fudan, PUMCH, Sun Yat-sen. Not yet standard-of-care but moving fast.
• Armored CAR-T (cytokine support, CRISPR-edited) — multiple early trials.

Success rates (consistent with global data):

• R/R DLBCL: complete response 50-70%, durable CR at 2+ years in 30-40% (ZUMA-1, JULIET, TRANSCEND). Chinese real-world data from Fudan and Yanda Ludaopei shows similar response rates.
• R/R multiple myeloma: overall response 70-90%, CR 30-50% with BCMA-targeted CAR-T.
• R/R B-ALL: CR 70-90% in pediatric and young adult patients.

Where to get CAR-T in China: Hebei Yanda Ludaopei Hospital (most experienced, most active trials); Fudan Shanghai Cancer Center (top academic, lymphoma CAR-T); PUMCH Hematology (ALL, lymphoma, trial CAR-T); Tongji Hospital Shanghai (second major center, often shorter wait); Beijing Cancer Hospital (lymphoma CAR-T).

Practical realities:

• Inpatient stay 4-6 weeks minimum for autologous CAR-T.
• Companion essentially mandatory — patient will be too ill to manage alone during CRS/ICANS risk window (days 3-14 post-infusion).
• Cost for commercial CAR-T in China: $50,000-100,000 for the drug + $10,000-25,000 for hospital fees, leukapheresis, supportive care, ICU monitoring. Total: $60,000-125,000.
• Cost for clinical trial CAR-T: trial drug usually free, you cover hospital fees, leukapheresis, scans, travel. Total: $15,000-40,000.
• Side effects: CRS (50-90% incidence, 5-15% severe), ICANS (20-60%, mostly reversible), prolonged cytopenia (30-50%), B-cell aplasia with hypogammaglobulinemia (requires IVIG for 6-12+ months), HLH (rare but serious), and second primary malignancies (rare, monitoring ongoing).
• Don’t go to a center without deep CAR-T experience — ICU and hematology support are essential. The top 4 centers above all have 100+ CAR-T cases per year.

Is China CAR-T safe? The products are produced at NMPA-audited facilities (often the same global contract manufacturers as US CAR-T) and have comparable response and toxicity profiles to US data. Clinical management is at the same international standard at the top 4-5 centers. Main safety variables are (a) the specific center’s CAR-T volume and (b) ICU and hematology support available.

Oncology clinical trials in China

China’s oncology clinical trial portfolio is now the 2nd largest in the world, and for some indications (3rd-generation EGFR inhibitors, novel bispecific antibodies, allogeneic CAR-T), Chinese trials are the only place to access cutting-edge drugs outside the US.

Scale of Chinese oncology trials:

• 4,800+ active oncology trials in China (vs 7,000+ in the US, 1,500+ in the EU, per ClinicalTrials.gov and chinadrugtrials.org.cn data, 2026).
• 1,200+ Phase 1, 2,400+ Phase 2, 1,200+ Phase 3.
• 60+ Chinese-developed novel oncology drugs approved in China since 2018, with 15+ approved by US FDA or EMA in the same period (e.g., zanubrutinib/百济神州, surufatinib/和黄, fruquintinib/和黄, toripalimab/君实).
• China leads globally in bispecific antibody development (e.g., cadonilimab/康方 PD-1xVEGF, ivonescimab/康方 PD-1xVEGF which is the first Phase 3 to beat pembrolizumab in NSCLC).
• China leads in next-generation KRAS inhibitors, allogeneic CAR-T, and several ADC platforms.

Top trial categories for foreign patients:

• 3rd-generation EGFR inhibitors (lung cancer) — multiple Chinese trials targeting C797S resistance mutation, often combined with chemotherapy or 1st-gen EGFR TKI. For NSCLC with EGFR resistance to osimertinib, Chinese trials are the most accessible option.
• Bispecific antibodies — PD-1xVEGF (cadonilimab, ivonescimab), PD-1xCTLA-4, BCMAxCD3, CD20xCD3, HER2xHER2, and many others across solid and hematologic tumors.
• Allogeneic (“off-the-shelf”) CAR-T — multiple Phase 1/2 trials for B-cell lymphoma, multiple myeloma, select solid tumors. No apheresis, no manufacturing wait.
• Dual-target and armored CAR-T — CD19/CD22 for lymphoma, BCMA/GPRC5D for myeloma, armored constructs with cytokine support.
• Next-generation ADCs — HER2, HER3, TROP2, CLDN18.2, Nectin-4, and other targets, often in indications where US ADCs are not yet approved.
• Cancer vaccines and personalized neoantigen vaccines — early-phase at Fudan, PUMCH, several biotech sites.
• Combination immunotherapy — PD-1/VEGF bispecific + chemo, PD-1 + LAG-3, and other novel combinations for first-line solid tumors.

How to find and access Chinese oncology trials:

1. Search ClinicalTrials.gov with China filter and your indication. Most Chinese-led trials are also registered here. Filter by phase, status (recruiting), and location.
2. Search chinadrugtrials.org.cn (中国药物临床试验登记与信息公示平台) for Chinese-led trials that may not be on ClinicalTrials.gov. The site is in Chinese but Google Translate handles it adequately.
3. Email the international patient center of the top 4-5 cancer hospitals (Fudan, PUMCH, Beijing Cancer, Sun Yat-sen, West China) with diagnosis, stage, molecular markers, prior treatment, and recent scans. The coordinator will match you to open trials and provide preliminary eligibility assessment.
4. Engage a medical tourism concierge (Trip.com or specialized agencies) to facilitate trial screening and invitation letter.

Practical realities:

• Trial drug is usually free.
• You cover: hospital fees, scans, lab work, travel, accommodation, companion.
• Total cost for 3-6 month trial participation: $10,000-30,000.
• Phase 1 trials have higher unknown-risk profile but may offer the only access to truly novel mechanisms.
• Phase 2/3 are usually safer bets if your disease is common enough.
• Ethics committee approval takes 2-4 weeks after matching.
• Bring all English medical records plus biopsy slides for central pathology review.
• For rare cancers, you may need to wait for a specific cohort to open.
• M-visa is the standard pathway for trial participation (240h transit is usually too short).

Important caveat: Clinical trials carry risk. Phase 1 trials are first-in-human with incompletely understood toxicity profiles. Read the informed consent carefully, ask about prior patient outcomes in the trial (if any), and discuss with your home oncologist before enrolling.

Integrated Chinese-Western oncology: TCM as supportive care

TCM is integrated into cancer care at every top Chinese oncology hospital — used as supportive care alongside Western oncology, not as a substitute. If you’re coming to China for cancer treatment, strongly consider adding TCM to your protocol.

What TCM is evidence-supported for in cancer care (per Cochrane reviews, China Clinical Oncology Guidelines, CSCO 2024-2025):

• Chemotherapy-induced nausea and vomiting (CINV): acupuncture at PC6 (内关) and auricular acupuncture, plus herbal formulas like Xiangsha Liujunzi (香砂六君子) and Banxia Houpo Tang (半夏厚朴汤), reduce CINV 30-50% on top of standard antiemetics. This is the single most consistent TCM benefit in oncology and is recommended in CSCO guidelines.
• Cancer-related fatigue (CRF): ginseng-based formulas (Ren Shen / 人参), acupuncture at ST36 (足三里) and SP6 (三阴交), and Tai Chi show benefit in randomized trials. CSCO includes TCM for moderate-severe CRF.
• Chemotherapy-induced bone marrow suppression: herbal formulas (Shiquan Dabu Tang / 十全大补汤, Dang Gui Bu Xue Tang / 当归补血汤) and acupuncture at ST36 support WBC, RBC, and platelet counts during chemo.
• Cancer pain: acupuncture is in WHO and NCCN guidelines for cancer pain as adjunctive therapy. Reduces opioid requirement 20-30% in some trials.
• Post-surgical recovery: TCM accelerates GI function recovery, reduces post-op ileus, supports wound healing.
• Immunomodulation during immunotherapy: Astragalus-based formulas (黄芪) and other Qi-tonifying herbs studied for immune support during checkpoint inhibitor therapy.
• Radiation-induced mucositis and dermatitis: herbal mouthwashes and topical preparations reduce severity.
• Lymphedema after breast cancer surgery: acupuncture and Tuina (推拿) reduce swelling and improve function.

What TCM is NOT a substitute for: primary cancer treatment; acute infections during neutropenia (use antibiotics); cytokine release syndrome after CAR-T (use tocilizumab and ICU care); tumor lysis syndrome (use allopurinol/rasburicase); emergency complications (call 120 immediately).

Top TCM-cancer integrated hospitals: Beijing (Dongzhimen Hospital TCM Oncology / 北京中医药大学东直门医院, China-Japan Friendship Hospital TCM Department); Shanghai (Longhua Hospital TCM Oncology / 上海中医药大学附属龙华医院, Yueyang Hospital); Guangzhou (Guangdong Provincial TCM Hospital Oncology / 广州中医药大学第一附属医院); Chengdu (Chengdu TCM University附属医院). Inside top cancer hospitals: Fudan Shanghai Cancer Center, PUMCH, Beijing Cancer Hospital, Sun Yat-sen, West China — all have integrated TCM oncology departments.

Cost of TCM supportive care: $50-150/acupuncture session; $30-80/cupping; $50-200/week herbal medicine; $80-200 for full TCM oncology consultation (60-90 min); $1,500-4,000 for integrated 14-day TCM-cancer support program. Often billed as part of the same hospital visit, direct-billable to international insurance.

Critical caveats:

• Tell your TCM doctor every Western drug you’re taking — herbal medicine can interact with chemo (especially CYP3A4-metabolized drugs like taxanes, TKIs), anticoagulants, immunosuppressants, and immunotherapy.
• Don’t use TCM as a substitute for evidence-based oncology — the role of TCM is supportive care.
• Avoid informal TCM clinics — stick to the TCM department of a registered tertiary-A hospital.
• Avoid herbal medicine during the immediate peri-CAR-T period (risk of hepatotoxicity and drug interaction during cytokine storm).

For a deeper dive on TCM, see our TCM & wellness guide and the medical tourism wellness article.

Hainan Boao for cutting-edge US/EU cancer drugs

Hainan Boao Lecheng International Medical Tourism Pilot Zone (海南博鳌乐城) is the only place in mainland China where a foreigner can legally access US FDA-approved drugs and devices that have not yet been approved by the Chinese NMPA. For cancer patients, this is sometimes the entire reason to come to China.

What Boao is and why it exists: Boao is a government-designated special zone in Hainan province (1 hour flight from Beijing/Shanghai, or 30 minutes from Sanya). Set up in 2013, the zone allows licensed medical institutions to use drugs and devices approved by the US FDA, EMA, or other reference regulators but not yet by China’s NMPA, provided the patient signs informed consent and the drug is for a serious condition. For cancer patients, this means access to cutting-edge drugs sometimes 1-3 years before they become available in mainland China.

Real use cases for cancer patients (as of 2026):

• Specific ADCs not yet NMPA-approved (certain HER3, TROP2, CLDN18.2 ADCs in the pipeline).
• Next-generation targeted therapies (KRAS G12C inhibitors in indications not yet NMPA-approved, novel FGFR inhibitors, IDH1/2 inhibitors).
• Cutting-edge immunotherapies (LAG-3 inhibitors, TIGIT inhibitors, novel combinations not yet NMPA-approved).
• Investigational drugs in expanded access (sometimes the only way to access certain drugs before Phase 3 read-out).
• CAR-T products in clinical trials (Boao has facilities running allogeneic CAR-T and next-generation CAR-T trials).
• Rare-disease cancer drugs (some pediatric and ultra-rare cancer drugs are available in Boao 1-2 years before NMPA approval).

Top Boao facilities for cancer: Boao Evergrande International Hospital (博鳌恒大国际医院, the original Boao flagship, affiliated with Brigham and Women’s Hospital); Boao Super Hospital (博鳌超级医院, multi-specialty, strong oncology program); Boao International Hospital (博鳌国际医院, newer, affiliated with multiple international centers); Hainan Cancer Hospital Boao Branch (dedicated cancer facility within the zone).

Practical realities of Boao cancer treatment:

• Boao stays are typically 2-4 weeks per drug course (shorter than full treatment trips to Beijing/Shanghai).
• Cost is at the higher end of Chinese healthcare — these are cutting-edge drugs with US-comparable pricing, often $20,000-100,000+ per course depending on the drug.
• M-visa is the standard pathway (240h transit is too short for most Boao cancer courses).
• Many Boao facilities require an invitation letter from the Boao facility itself, plus a hospital referral from your home oncologist.
• For clinical trials at Boao, drug is usually free but you cover hospital fees, scans, and travel.
• The Boao zone has its own English-speaking coordinators, and most facilities have direct-billing with major international insurers.

For most foreign cancer patients: Boao is the right choice ONLY if you specifically need a US FDA-approved drug not yet available in mainland China. If a Chinese-approved alternative exists (and for most common cancers, it does), Beijing or Shanghai is more cost-effective and has deeper specialty experience. For the 10-20% of cases where the needed drug is US-only, Boao is the only option.

Realistic example: A US patient with KRAS G12C-mutated NSCLC who progressed on sotorasib (the US-approved KRAS G12C inhibitor) and needs a next-generation KRAS inhibitor that is FDA-approved but not NMPA-approved. Boao is the right call. A patient with newly diagnosed EGFR-mutant NSCLC who could get osimertinib (Tagrisso) at Fudan Shanghai for $5,000-15,000/year should go to Shanghai, not Boao.

See our Boao deep dive guide for the full Boao framework.

How to get a second opinion from a top Chinese cancer hospital

A second opinion from a top Chinese cancer hospital is one of the highest-leverage uses of medical tourism to China. The process is well-established, affordable ($500-2,000 for a full written second opinion), and the top centers have senior US/UK-trained pathologists and oncologists who can re-review your case.

When to get a second opinion from China: your home oncologist is recommending a treatment and you want a sanity check from a top Chinese center (especially for rare cancers, late-stage, treatment-refractory); your home country doesn’t have a specific treatment or drug you need; you want to confirm a diagnosis or pathology (Chinese tertiary-A hospitals have some of the world’s most experienced pathologists for certain cancers, especially NPC, gastric, liver, esophageal); you’re considering a clinical trial and want an outside assessment; your insurance requires a second opinion for treatment authorization.

Step-by-step process:

Step 1: Gather your records (2-4 weeks before contacting the hospital): written English diagnosis (cancer type, stage, molecular markers like HER2/PD-L1/EGFR/BRCA/KRAS/NTRK); most recent CT/MRI/PET scans (DICOM files on a CD or downloadable link — most Chinese hospitals accept both); biopsy pathology report, plus the original biopsy slides if possible; 1-page treatment summary from your home oncologist; list of all prior treatments, doses, dates, and response; recent bloodwork (CBC, CMP, tumor markers).

Step 2: Email the international patient center of 2-3 top hospitals. Send the same package to the international center of 2-3 top hospitals (e.g., Fudan Shanghai + PUMCH + Sun Yat-sen). Request: availability for a written second opinion ($500-2,000) or in-person consultation; cost estimate for any recommended workup (repeat biopsy, repeat scans, molecular profiling); whether the diagnosis or treatment plan differs from your home oncologist’s; whether clinical trial options exist for your case; M-visa invitation letter if needed.

Step 3: Receive the written second opinion (2-4 weeks): most top hospitals have a formal second-opinion service, with turnaround 2-4 weeks for written opinions, 1-2 weeks for expedited; the opinion usually comes from a senior attending (主任医师) or chief physician, often reviewed by a multidisciplinary tumor board; cost: $500-2,000 for a written second opinion (not including repeat scans or biopsy if needed); the opinion will typically cover: confirmation/refinement of diagnosis, recommended workup, recommended treatment plan, alternative options, and clinical trial availability.

Step 4: Decide whether to proceed with treatment in China:

• If the second opinion agrees with your home oncologist: proceed with confidence at home or in China, whichever is more cost-effective.
• If the second opinion differs: discuss with your home oncologist. In some cases (rare cancers, late-stage, treatment-refractory), the Chinese opinion may be more informed due to higher volume.
• If the second opinion identifies a clinical trial option not available at home: consider enrollment in China (M-visa required).

Top hospitals for second opinions: PUMCH Oncology (best for complex solid tumors, rare cancers); Fudan Shanghai Cancer Center (best for breast, gastric, colorectal, lymphoma, high-volume pathology review); Beijing Cancer Hospital (NCC, best for lung, esophageal, lymphoma, head & neck); Sun Yat-sen Cancer Center (SYSUCC, best for NPC, liver, breast, SE Asian patients); West China Hospital (best for western China residents).

For more on the second-opinion process, see our how to choose a hospital guide.

Insurance, payment, and cost realities for cancer patients

The honest reality: most international health insurance does NOT cover pre-existing cancer treatment abroad. Most foreign cancer patients in China self-pay, and the 50-85% cost savings are still dramatic.

Insurance options:

The realistic insurance path for cancer patients:

1. Buy a medical evacuation policy (International SOS, Medjet, Global Rescue) for safety net — covers emergency evacuation to a higher-level center if complications arise. $200-500/month.
2. Self-pay for the cancer treatment (with the 50-85% cost savings, this is the rational economic choice for many patients).
3. Some US patients use medical loans (e.g., Scratchpay, CareCredit for international procedures) or personal medical fundraising (GoFundMe) to finance the trip.
4. Some employers or national health systems (UK NHS, EU national health, Canadian provincial health) may cover part of the cost for specific treatments — check with your case manager.

Payment logistics at Chinese cancer hospitals:

• Wire transfer (most common for large treatment costs).
• Credit card (Visa/Mastercard/Amex, 2-3% foreign transaction fee, $10,000-30,000 typical limit per transaction).
• Cash USD or RMB (for smaller amounts).
• Alipay+ (Alipay linked to Visa/Mastercard, no fee, increasing limit).
• Hospital billing in English with itemized receipts (essential for reimbursement or US tax deduction).
• Direct-billing with international insurers (for emergencies, clinical trial hospital fees, second opinions).

Hidden costs to budget for: repeat scans, biopsies, molecular profiling ($1,000-5,000); tumor board review fee ($500-2,000); medical record translation if not English ($500-2,000); companion accommodation ($2,000-5,000 for 30-60 days); post-treatment medications to take home ($1,000-5,000); fit-to-fly certificate (usually free); long-term follow-up imaging (usually done at home after return).

For the broader insurance framework, see our insurance & payment guide.

Sample 30-60 day cancer treatment itinerary (Beijing + Boao)

A typical 6-8 week mid-tier trip for one cancer treatment course (e.g., 1 CAR-T cycle, 1 allogeneic transplant, 1 major surgery + adjuvant therapy, or 3-6 months of chemo/immunotherapy), with 1 companion. Realistic budget for a Beijing-first, Boao-optional itinerary.

Realistic per-treatment cost breakdowns (all-in, including the above itinerary):

• CAR-T (commercial): $60,000-125,000 (drug + hospital + 4-6 week stay).
• CAR-T (clinical trial): $25,000-50,000 (hospital + trial fees + 4-6 week stay; drug is free).
• Allogeneic HSCT: $80,000-150,000 (transplant + 8-12 week stay + 6 months follow-up planning).
• Major surgery (e.g., Whipple, gastrectomy) + 3 months chemo: $30,000-60,000.
• 3 months of chemo + immunotherapy (e.g., NSCLC): $20,000-50,000.
• 6 months of chemo + targeted therapy (e.g., EGFR+ lung cancer): $40,000-80,000.
• Boao US drug add-on: $20,000-100,000 (drug-dependent).

The same treatment in the US for comparison: CAR-T (commercial) $300,000-500,000+ (drug only, hospital extra); allogeneic HSCT $300,000-800,000+; major cancer surgery + 3 months chemo $150,000-300,000; 6 months of chemo + targeted therapy $200,000-400,000.

So for a typical 6-8 week Beijing + Boao trip with 1 companion, you’re looking at $40,000-140,000 vs $200,000-500,000+ in the US. The savings are real, and the quality at the top 4-5 Chinese oncology centers is genuinely equivalent for most adult cancers.

For the broader itinerary framework, see our medical tourism P0 guide and medical visa guide.

Plan your cancer treatment trip to China

All of the trip logistics (flights, hotel, airport pickup, hotel-hospital transfer) can be booked through Trip.com, often 20-30% cheaper than Western OTAs for the same flights and hotels. The three most-asked-about affiliate cards for cancer patients traveling to China:

For insurance, see our insurance & payment guide for direct-billing options and medical evacuation policy recommendations. For emergency healthcare during your stay, see sick in China guide. For TCM supportive care, see TCM & wellness guide and TCM & wellness article. For city-specific deep dives, see Beijing guide, Shanghai guide, Boao guide, and Chengdu guide.

For the broader medical tourism framework, see the P0 medical tourism guide, medical visa guide, and how to choose a hospital guide.

Related: China medical tourism 2026 guide

Related: China TCM foreigners guide

Related: China sick in foreigners guide